Is Amgen (AMGN) overvalued or fairly valued?

MarketChacha shows Amgen's valuation in context — a forward P/E of about 15.6, a price-to-book of about 21.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Amgen (AMGN)?

Amgen last traded at $364.17 (-0.6% on the day), as of 7/20/2026 — a delayed quote shown for education, not investment advice.

Amgen

AMGN · NASDAQ · Biotech · United States

$364.17-0.6%

Delayed · as reported by Yahoo Finance · as of Jul 20, 2026, 8:00 PM

Snapshot

TickerAMGN

ExchangeNASDAQ

SectorBiotech

IndustryDrug Manufacturers - General

CountryUnited States

Employees31,500

HeadquartersThousand Oaks, United States

Market cap$197.0B

P/B21.4

Volume1.73M

Websitewww.amgen.com

Filings tracked0

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.2%
Institutions86.5%
Public & other13.3%

3,934 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.8.73%
Vanguard Capital Management LLC6.49%
State Street Corporation5.66%
Capital World Investors5.43%
Invesco Ltd.2.94%
Morgan Stanley2.93%
Geode Capital Management, LLC2.86%
Vanguard Portfolio Management LLC2.71%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $9.7B · EPS 5.74

Est. earnings growth +1.8%

Next fiscal year

Rev $38.7B · EPS 23.45

Est. earnings growth +5.0%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$269.7752-wk range$391.29

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about AMGN

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.